title: Intestinal transplantation in children: preliminary experience in Paris.
abstract: From November 1994 to November 1998, 20 children (2.5 to 14 years) received a jejunoileal graft alone (SBTx; n = 10) or in combination with the liver (SBLTx; n = 10 and/or the right colon (5 SBTx). Indications were intractable diarrhea of infancy (n = 8), short bowel syndrome (n = 6), extensive Hirschsprung disease (n = 4), and chronic intestinal pseudoobstruction (n = 2). Immunosuppression included tacrolimus, methylprednisolone, and azathioprine. Current follow-up ranges from 6 to 54 months. Five patients died (3 SBTx) within the first 2 months. Acute liver rejection occurred in 5 patients during the first 2 months. Sixteen episodes of intestinal rejection during the first 3 months in 11 patients (8 in 4 SBTx) were successfully treated in all but 3 by increasing tacrolimus dose and/or a 3-day methyprednisolone bolus or required antilymphoglobulins in 3 cases. Surgical complications occurred 8 times after SBLTx and 3 after SBTx. Infectious complications were more frequent in SBLTx recipients. Reversible Epstein-Barr virus-related posttransplant lymphoproliferative disease occurred in 3 recipients. Five presented cytomegalovirus infection. The SB graft was removed in 5 recipients (3 chronic rejection). All patients were started with oral and/or enteral feeding from the 7th postoperative day by using either normal food or protein hydrolysate diet. Currently, 10 of 11 children (8 SBLTx) achieved digestive autonomy after 5 to 30 weeks. All recipients gained weight; however, growth velocity remained reduced during the first 6 months because of the steroid therapy. Overall graft and patient survival is higher after SBLTx. Intestinal transplantation is indicated for patients with permanent intestinal failure. However, because parenteral nutrition is generally well tolerated, even for long periods, each indication for transplantation must be weighed carefully in terms of risk and quality of life.
authors.affiliation: Combined Program of Liver and Intestinal Transplantation, Hôpital Necker-Enfants Malades, Paris, France.
authors.forename: O
authors.initials: O
authors.lastname: Goulet
authors.forename: D
authors.initials: D
authors.lastname: Jan
authors.forename: F
authors.initials: F
authors.lastname: Lacaille
authors.forename: V
authors.initials: V
authors.lastname: Colomb
authors.forename: J L
authors.initials: JL
authors.lastname: Michel
authors.forename: D
authors.initials: D
authors.lastname: Damotte
authors.forename: P
authors.initials: P
authors.lastname: Jouvet
authors.forename: N
authors.initials: N
authors.lastname: Brousse
authors.forename: C
authors.initials: C
authors.lastname: Faure
authors.forename: J P
authors.initials: JP
authors.lastname: Cézard
authors.forename: S
authors.initials: S
authors.lastname: Sarnacki
authors.forename: M
authors.initials: M
authors.lastname: Peuchmaur
authors.forename: P
authors.initials: P
authors.lastname: Hubert
authors.forename: C
authors.initials: C
authors.lastname: Ricour
authors.forename: Y
authors.initials: Y
authors.lastname: Révillon
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D003968:Diarrhea, Infantile / Q000188:drug therapy / Q000601:surgery*; D005260:Female; D006085:Graft Survival; D006627:Hirschsprung Disease / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007223:Infant; D007239:Infections / Q000188:drug therapy / Q000401:mortality; D007422:Intestines / Q000637:transplantation*; D016031:Liver Transplantation; D008297:Male; D010297:Paris; D011183:Postoperative Complications / Q000188:drug therapy / Q000401:mortality; D012778:Short Bowel Syndrome / Q000188:drug therapy / Q000601:surgery*; D015996:Survival Rate
chemical_list: D016572:Cyclosporine